Current Hepatitis Reports

, Volume 2, Issue 3, pp 101–107

Hepatitis C antiviral treatment in special populations

  • Helen S. Yee
  • Teresa L. Wright


Early identification and consideration for antiviral treatment of chronic hepatitis C virus (HCV) is an important component in reducing morbidity and mortality. Although many HCV-infected patients do not meet current criteria for antiviral therapy, increased efforts are needed to overcome barriers to care and improve treatment candidacy. In select patients, clinicians should consider expanding treatment eligibility to reduce disease progression, lifethreatening complications, and future disease burden. Preliminary data suggest that HCV-infected "special populations," including those with substance abuse disorders (ie, injection drug use, alcohol abuse), those coinfected with HIV, and those with cirrhosis but only mild hepatic compromise, can be successfully treated with interferonbased preparations and ribavirin. Larger, controlled clinical studies are needed to validate preliminary results. Collaboration with a multidisciplinary team experienced in managing HCV infection is crucial to improve treatment candidacy, address the complexities involved with treating special populations, and optimize response and ensure safety in those undergoing HCV antiviral therapy.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998, 47(No. RR-19):1-39. Publications/mmwr/rr/rr4719.pdfGoogle Scholar
  2. 2.
    Poynard T, Mathurin P, Lai C, et al.: A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003, 38:257–265.PubMedCrossRefGoogle Scholar
  3. 3.
    Benhamou Y, Bochet M, Di Martino V, et al.: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. Hepatology 1999, 30:1054–1058.PubMedCrossRefGoogle Scholar
  4. 4.
    Wiley TE, McCarthy M, Breidi L, Layden TJ: Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998, 28:805–809.PubMedCrossRefGoogle Scholar
  5. 5.
    Muir AJ, Provenzale D: A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. J Clin Gastroenterol 2002, 34:268–271.PubMedCrossRefGoogle Scholar
  6. 6.
    Garfein RS, Vlahov D, Galai N, et al.: Viral infections in shortterm injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996, 86:655–661.PubMedGoogle Scholar
  7. 7.
    Zeldis JB, Jain S, Kuramoto IK, et al.: Seroepidemiology of viral infections among intravenous drug users in Northern California. West J Med 1992, 156:30–35.PubMedGoogle Scholar
  8. 8.
    Briggs ME, Baker C, Hall R, et al.: Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center. Hepatology 2001, 34:1200–1205.PubMedCrossRefGoogle Scholar
  9. 9.
    Hagan H, Thiede H, Weiss NS, et al.: Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001, 91:42–46.PubMedCrossRefGoogle Scholar
  10. 10.
    Hahn JA, Page-Shafer K, Lum PJ, et al.: Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001, 34:180–187.PubMedCrossRefGoogle Scholar
  11. 11.
    Patrick DM, Tyndall MW, Cornelisse P, et al.: Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 2001, 165:889–895.PubMedGoogle Scholar
  12. 12.
    Li K, Sherlock CH, Thorpe LE, et al.: Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002, 155:645–653.CrossRefGoogle Scholar
  13. 13.
    NIH Consensus Development Conference Statement: Management of Hepatitis C: 2002. June 10–12, 2002. Vol 19, No 1. Final statement September 12. http://consensus. 2002.Google Scholar
  14. 14.
    Ono K, Sata M, Murashima S, et al.: Biological responses to administered interferon in alcoholics. Alcohol Clin Exp Res 1996, 20:1560–1563.PubMedCrossRefGoogle Scholar
  15. 15.
    Ohnishi K, Matsuo S, Matsutani K, et al.: Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996, 91:1374–1379.PubMedGoogle Scholar
  16. 16.
    Schiff ER: The alcoholic patient with hepatitis C virus infection. Am J Med 1999, 107:95S-99S.PubMedCrossRefGoogle Scholar
  17. 17.
    Stephenson J: Former addicts face barriers to treatment for HCV. JAMA 2001, 285:1003–1005.PubMedCrossRefGoogle Scholar
  18. 18.
    Backmund M, Meyer K, Von Zielonka M, Eichenlaub D: Treatment of hepatitis C infection in injection drug users. Hepatology 2001, 34:188–193. In an observational study with 50 HCV-infected patients on MMT, 36% achieved SVR with standard interferon and ribavirin when treated for 24 to 48 weeks.PubMedCrossRefGoogle Scholar
  19. 19.
    Sylvestre DL: Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002, 67:117–123. In an observational study with 50 HCV-infected patients on MMT, 54% achieved an EOT virologic response with standard interferon and ribavirin when treated for 24 to 48 weeks.PubMedCrossRefGoogle Scholar
  20. 20.
    Poynard T, Marcellin P, Lee SS, et al.: Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus ribavirin for 48 weeks for the treatment of chronic infection with hepatitis c virus. Lancet 1998, 352:1426–1432.PubMedCrossRefGoogle Scholar
  21. 21.
    McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485–1492.PubMedCrossRefGoogle Scholar
  22. 22.
    Sherman KE, Rouster SD, Chung RT, Rajicic N: Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002, 34:831–837.PubMedCrossRefGoogle Scholar
  23. 23.
    Bräu N, Bini EJ, Shahidi A, et al.: Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol 2002, 97:2071–2078.PubMedGoogle Scholar
  24. 24.
    Soriano V, Sulkowski M, Bergin C, et al.: Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002, 16:813–828. Expert panel review and recommendations on the magnitude of the problem, disease progression, management, and treatment challenges involved with caring for persons coinfected with HCV and HIV.PubMedCrossRefGoogle Scholar
  25. 25.
    Sulkowski MS, Thomas DL: Hepatitis C in the HIV-infected person. Ann Intern Med 2003, 138:197–207. A concise review of the epidemiology, natural history, pathogenesis, diagnosis, management, and treatment of persons coinfected with HCV and HIV.PubMedGoogle Scholar
  26. 26.
    Villano SA, Vlahov D, Nelson KE, et al.: Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbiol 1997, 35:3274–3277.PubMedGoogle Scholar
  27. 27.
    Di Martino V, Rufat P, Boyer N, et al.: The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001, 34:1193–1199.PubMedCrossRefGoogle Scholar
  28. 28.
    Centers for Disease Control and Prevention: Guidelines for preventing opportunistic infections among HIV-infected persons - 2002: Recommendations of the U.S. Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR 2002, 51(No. RR-8):21-22.Google Scholar
  29. 29.
    Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996, 334:1685–1690.PubMedCrossRefGoogle Scholar
  30. 30.
    Eyster ME, Alter HJ, Aledort LM, et al.: Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency (HIV). Ann Intern Med 1991, 115:764–768.PubMedGoogle Scholar
  31. 31.
    Graham CS, Baden LR, Yu E, et al.: Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33:562–569.PubMedCrossRefGoogle Scholar
  32. 32.
    Chung R, Anderson J, Alston B, et al.: A randomized, controlled trial of pegylated interferon alfa-2a with ribavirin vs interferon alfa-2a with ribavirin for the treatment of chronic HCV in HIV co-infection: ACTG A5071. Late Breaker Abstract 15 (oral). Paper presented at the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA. February 24–28, 2002.Google Scholar
  33. 33.
    Perronne C, Carrat F, Bani Sadr F, et al.: A randomized controlled trial of pegylated-interferon alfa-2b plus ribavirin vs interferon alfa-2b plus Ribavirin for the Initial Treatment of Chronic Hepatitis C in HIV co-infected patients. Abstract 1083. Paper presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA. September 27–30, 2002.Google Scholar
  34. 34.
    Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74–80.PubMedCrossRefGoogle Scholar
  35. 35.
    Sulkowski MS, Thomas DL, Mehta SJ, et al.: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002, 35:182–189.PubMedCrossRefGoogle Scholar
  36. 36.
    Dieterich D, Stern J, Robinson P, et al.: Analyses of four clinical trials to assess the risk of hepatotoxicity with nevirapine: correlation with CD4+ levels, hepatitis B and C seropositivity, and baseline liver function tests. Paper presented at the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina. July 8–11, 2001.Google Scholar
  37. 37.
    Bruno R, Sacchi P, Filice G: Mitochondrial toxicity in HIV-HCV coinfection: it depends of the choice of antiretroviral drugs. Hepatology 2002, 35:500–501.PubMedCrossRefGoogle Scholar
  38. 38.
    Lafeuillade A, Hittinger G, Chadapaud S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001, 357:280–281.PubMedCrossRefGoogle Scholar
  39. 39.
    Hor R, Deshayes J, Banisadr F, et al.: Concomitant DDI/D4T and interferon (standard or pegylated IFN)/ribavirin treatments may induce a high risk of mitochondrial toxicity in HIV/HCV co-infected patients (ANRS HC02-RIBAVIC Study) [abstract]. Hepatology 2002, 36:481A.Google Scholar
  40. 40.
    Fattovich G, Giustina G, Degos F, et al.: Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997, 112:463–472.PubMedCrossRefGoogle Scholar
  41. 41.
    Davis GL, Albright JE, Cook SF, Rosenberg DM: Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003, 9:331–338.PubMedCrossRefGoogle Scholar
  42. 42.
    Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958–965.PubMedCrossRefGoogle Scholar
  43. 43.
    Fried MW, Shiffman ML, Reddy RK, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975–982.PubMedCrossRefGoogle Scholar
  44. 44.
    Wright T: Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002, 36:S185-S194.PubMedCrossRefGoogle Scholar
  45. 45.
    Charlton M, Seaberg E, Wiesner R, et al.: Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998, 28:823–830.PubMedCrossRefGoogle Scholar
  46. 46.
    Everson GT, Trouillot T, Trotter J, et al.: Treatment of decompensated cirrhotics with a slow-accelerating dose regimen (LADR) of interferon-alfa-2b plus ribavirin: safety and efficacy [abstract]. Hepatology 2000, 32:308A.CrossRefGoogle Scholar
  47. 47.
    Crippin JS, Sheiner P, Terrault NA, et al.: A pilot study of the tolerability and efficacy of antiviral therapy in patients awaiting liver transplantation for hepatitis C. Liver Transpl 2002, 8:350–355.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2003

Authors and Affiliations

  • Helen S. Yee
    • 1
  • Teresa L. Wright
    • 1
  1. 1.Department of Veterans Affairs Medical CenterSan Francisco, GI Section (111B)San FranciscoUSA

Personalised recommendations